Publications by authors named "Dominick Yeo"

Claim this Profile
P
Preclinical Characterization of XB010: A Novel Antibody-Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4.
Brian A Mendelsohn, Kathleen R Gogas, Jeffrey N Higaki, Willy A Solis, Inna Vainshtein, Dominick Y Yeo

Mol Cancer Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A metabolic inhibitor blocks cellular fucosylation and enables production of afucosylated antibodies.
Pierre-André Gilormini, V Narasimharao Thota, Anthony Fers-Lidou, Roger A Ashmus, Matthew Nodwell, Dominick Yeo

Proc Natl Acad Sci U S A· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody-Drug Conjugates.
Stepan Chuprakov, Ayodele O Ogunkoya, Robyn M Barfield, Maxine Bauzon, Colin Hickle, Dominick Yeo

Bioconjug Chem· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel HER2-targeted Antibody-drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels.
Robyn M Barfield, Yun Cheol Kim, Stepan Chuprakov, Fangjiu Zhang, Maxine Bauzon, Dominick Yeo

Mol Cancer Ther· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic LC/MS/MS Investigations for the IND-Enabling Extended Characterization of Antibody-Drug Conjugate Modifications.
Thomas Linz, Dominick Yeo, Qiuting Hong, Wesley Zmolek, Jesse McFarland

Antibodies (Basel)· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis